Abstract
Rationale: It has been claimed that phycocyanin exhibits pharmaceutical functions in inhibiting histamine release and leukotriene biosynthesis. In allergic asthma, these inflammatory mediators are crucial for disease progression. Objectives: The aim of this study was to evaluate the therapeutic potential of R-phycocyanin (R-PC) against allergic airway inflammation. Methods: Mousebone marrow - derived dendritic cells (BMDCs)were used to evaluate the immunomodulatory functions of R-PC. In addition, an airway inflammatory model was used to evaluate the therapeutic potential of R-PC. Measurements and Main Results: R-PC treatment resulted in a decrease of endocytosis, increase of costimulatory molecule expression, and enhancement of interleukin-12 production in mouse BMDCs. Moreover, R-PC - treated cultured dendritic cells were able to promote CD4+ T-cell stimulatory capacity and increase interferon-γ expression in CD4+ T cells. Intraperitoneal administration of R-PC suppressed ovalbumin (OVA)-induced airway hyperresponsiveness, serum levels of OVA-specific IgE and IgG1, eosinophil infiltration, Th2 cytokine levels, and eotaxin in bronchoalveolar lavage fluid of mice. Antibody against Toll-like receptor-4 was able to inhibit R-PC - induced IL-12 p70 production. Moreover, inhibition of nuclear factor-κB (NF-κB) by helenalin and inhibition of the JNK pathway by JNK inhibitor II inhibited R-PC - induced IL-12 p70 production. Western blotting and electrophoretic mobility shift assays showed that R-PC augmented phosphorylation of the inhibitors of NF-κB and inhibitors of NF-κB kinase and facilitated NF-κB activity. Conclusions: Our data demonstrated that R-PC promoted activation and maturation of cultured dendritic cells and skewed the immunological function toward Th1 activity. Therefore, R-PC may have potential in regulating immune responses and application in reducing allergic asthma.
| Original language | English |
|---|---|
| Pages (from-to) | 15-25 |
| Number of pages | 11 |
| Journal | American Journal of Respiratory and Critical Care Medicine |
| Volume | 183 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 1 2011 |
Fingerprint
Keywords
- Allergic asthma
- Immunomodulation
- R-phycocyanin
- Th1
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Critical Care and Intensive Care Medicine
Cite this
A novel phycobiliprotein alleviates allergic airway inflammation by modulating immune responses. / Chang, Chun Jung; Yang, Yao Hsu; Liang, Yu Chih; Chiu, Chiao Juno; Chu, Kuan Hua; Chou, Hung Non; Chiang, Bor Luen.
In: American Journal of Respiratory and Critical Care Medicine, Vol. 183, No. 1, 01.01.2011, p. 15-25.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A novel phycobiliprotein alleviates allergic airway inflammation by modulating immune responses
AU - Chang, Chun Jung
AU - Yang, Yao Hsu
AU - Liang, Yu Chih
AU - Chiu, Chiao Juno
AU - Chu, Kuan Hua
AU - Chou, Hung Non
AU - Chiang, Bor Luen
PY - 2011/1/1
Y1 - 2011/1/1
N2 - Rationale: It has been claimed that phycocyanin exhibits pharmaceutical functions in inhibiting histamine release and leukotriene biosynthesis. In allergic asthma, these inflammatory mediators are crucial for disease progression. Objectives: The aim of this study was to evaluate the therapeutic potential of R-phycocyanin (R-PC) against allergic airway inflammation. Methods: Mousebone marrow - derived dendritic cells (BMDCs)were used to evaluate the immunomodulatory functions of R-PC. In addition, an airway inflammatory model was used to evaluate the therapeutic potential of R-PC. Measurements and Main Results: R-PC treatment resulted in a decrease of endocytosis, increase of costimulatory molecule expression, and enhancement of interleukin-12 production in mouse BMDCs. Moreover, R-PC - treated cultured dendritic cells were able to promote CD4+ T-cell stimulatory capacity and increase interferon-γ expression in CD4+ T cells. Intraperitoneal administration of R-PC suppressed ovalbumin (OVA)-induced airway hyperresponsiveness, serum levels of OVA-specific IgE and IgG1, eosinophil infiltration, Th2 cytokine levels, and eotaxin in bronchoalveolar lavage fluid of mice. Antibody against Toll-like receptor-4 was able to inhibit R-PC - induced IL-12 p70 production. Moreover, inhibition of nuclear factor-κB (NF-κB) by helenalin and inhibition of the JNK pathway by JNK inhibitor II inhibited R-PC - induced IL-12 p70 production. Western blotting and electrophoretic mobility shift assays showed that R-PC augmented phosphorylation of the inhibitors of NF-κB and inhibitors of NF-κB kinase and facilitated NF-κB activity. Conclusions: Our data demonstrated that R-PC promoted activation and maturation of cultured dendritic cells and skewed the immunological function toward Th1 activity. Therefore, R-PC may have potential in regulating immune responses and application in reducing allergic asthma.
AB - Rationale: It has been claimed that phycocyanin exhibits pharmaceutical functions in inhibiting histamine release and leukotriene biosynthesis. In allergic asthma, these inflammatory mediators are crucial for disease progression. Objectives: The aim of this study was to evaluate the therapeutic potential of R-phycocyanin (R-PC) against allergic airway inflammation. Methods: Mousebone marrow - derived dendritic cells (BMDCs)were used to evaluate the immunomodulatory functions of R-PC. In addition, an airway inflammatory model was used to evaluate the therapeutic potential of R-PC. Measurements and Main Results: R-PC treatment resulted in a decrease of endocytosis, increase of costimulatory molecule expression, and enhancement of interleukin-12 production in mouse BMDCs. Moreover, R-PC - treated cultured dendritic cells were able to promote CD4+ T-cell stimulatory capacity and increase interferon-γ expression in CD4+ T cells. Intraperitoneal administration of R-PC suppressed ovalbumin (OVA)-induced airway hyperresponsiveness, serum levels of OVA-specific IgE and IgG1, eosinophil infiltration, Th2 cytokine levels, and eotaxin in bronchoalveolar lavage fluid of mice. Antibody against Toll-like receptor-4 was able to inhibit R-PC - induced IL-12 p70 production. Moreover, inhibition of nuclear factor-κB (NF-κB) by helenalin and inhibition of the JNK pathway by JNK inhibitor II inhibited R-PC - induced IL-12 p70 production. Western blotting and electrophoretic mobility shift assays showed that R-PC augmented phosphorylation of the inhibitors of NF-κB and inhibitors of NF-κB kinase and facilitated NF-κB activity. Conclusions: Our data demonstrated that R-PC promoted activation and maturation of cultured dendritic cells and skewed the immunological function toward Th1 activity. Therefore, R-PC may have potential in regulating immune responses and application in reducing allergic asthma.
KW - Allergic asthma
KW - Immunomodulation
KW - R-phycocyanin
KW - Th1
UR - http://www.scopus.com/inward/record.url?scp=78650791241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650791241&partnerID=8YFLogxK
U2 - 10.1164/rccm.201001-0009OC
DO - 10.1164/rccm.201001-0009OC
M3 - Article
C2 - 20709826
AN - SCOPUS:78650791241
VL - 183
SP - 15
EP - 25
JO - American Journal of Respiratory and Critical Care Medicine
JF - American Journal of Respiratory and Critical Care Medicine
SN - 1073-449X
IS - 1
ER -